Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY announces Pelareorep ≥50% ORR & mPFS Improvements

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 30, 2023 12:44pm

134 Views

Post# 35470537

RE:RE:RE:RE:RE:RE:ONCY announces Pelareorep ≥50% ORR & mPFS Improvements

And with ONCY's Phase 2 Bracelet-1 clinical data with ORR and PFS endpoints being surpassed, these results set up the scenario for ONCY that Evercore's note surmises.

May 17, 2023 - "Thawing of interest in mega-deals would invariably shift consolidation focus to smaller and earlier-stage biotech companies – and more of them," Evercore analysts said in a note.

<< Previous

Bullboard Posts

Next >>

Bombardier delivers Global 6500 aircraft to U.S. Army